Head to head
LivaNova vs Abbott Laboratories
Side-by-side on the measures that matter, with a plain-English read. Full detail: LIVN · ABT
LIVN
LivaNova
75.93+1.33%
1-year price shape — +46% over the period
Quant Rating B · 80/100
vs
ABT
Abbott Laboratories
98.73+0.58%
1-year price shape — -24% over the period
Quant Rating E · 15/100
1-year performance, rebased to 100
Abbott Laboratories edges it on the scoreable measures. Abbott Laboratories pays the highest dividend yield; Abbott Laboratories earns the most per share.
| LIVN | ABT | |
|---|---|---|
| Snapshot | ||
| Sector | Medical Devices | Medical Devices |
| Last price | 75.93 | 98.73 |
| Change today | +1.33% | +0.58% |
| 1-year return | +45.6% | -24.1% |
| Market cap | $4.18B | $170.84B |
| 52-week range | 48.82 – 85.76 | 81.39 – 130.33 |
| Valuation | ||
| P/E (TTM) | 22.40 | 31.95 |
| P/E percentile, own 5-yr range | 72nd | 62nd |
| P/B | 3.16 | 3.34 |
| Dividend yield | 0.00% | 2.47% |
| Profitability & growth | ||
| EPS (TTM) | -4.45 | 3.72 |
| Net profit (TTM) | $-245.17M | $6.44B |
| Revenue (TTM) | $1.47B | $46.59B |
| Revenue growth (YoY) | +10.8% | +13.0% |
| Gross margin | 68.1% | 56.6% |
| Operating margin | 12.7% | 15.8% |
| Net margin | 12.8% | 11.6% |
| Free cash flow (TTM) | $148.31M | $7.82B |
| Ownership & sentiment | ||
| Institutional ownership | 114.8% | 81.2% |
| Insider activity (12mo) | 30 buy / 19 sell | 36 buy / 12 sell |
| Short interest (% of float) | 9.8% | 1.1% |
| Analyst consensus | 100% buy (3) | 100% buy (14) |
| Analyst price target | $92 (+21%) | $125 (+26%) |
| StockVane view | ||
| StockVane Quant Rating | B (80) | E (15) |
| Company | ||
| Employees | 3,300 | 115,000 |
| Founded | 2015 | 1888 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.